These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 19726147)

  • 1. Evaluation of FibroTest-ActiTest in children with chronic hepatitis C virus infection.
    Hermeziu B; Messous D; Fabre M; Munteanu M; Baussan C; Bernard O; Poynard T; Jacquemin E
    Gastroenterol Clin Biol; 2010 Jan; 34(1):16-22. PubMed ID: 19726147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noninvasive assessment of hepatic fibrosis and necroinflammatory activity in Egyptian children with chronic hepatitis C virus infection using FibroTest and ActiTest.
    El-Shabrawi MH; Mohsen NA; Sherif MM; El-Karaksy HM; Abou-Yosef H; El-Sayed HM; Riad H; Bahaa N; Isa M; El-Hennawy A
    Eur J Gastroenterol Hepatol; 2010 Aug; 22(8):946-51. PubMed ID: 20110820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological markers of liver fibrosis and activity as non-invasive alternatives to liver biopsy in patients with chronic hepatitis C and associated mixed cryoglobulinemia vasculitis.
    Sène D; Limal N; Messous D; Ghillani-Dalbin P; Charlotte F; Thiollière JM; Piette JC; Imbert-Bismut F; Halfon P; Poynard T; Cacoub P
    Clin Biochem; 2006 Jul; 39(7):715-21. PubMed ID: 16765932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of the non-invasive serum marker FibroTest-ActiTest in the prediction of histological stage of fibrosis and activity in children with naïve chronic hepatitis B infection.
    Sökücü S; Gökçe S; Güllüoğlu M; Aydoğan A; Celtik C; Durmaz O
    Scand J Infect Dis; 2010 Sep; 42(9):699-703. PubMed ID: 20429710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies.
    Bourliere M; Penaranda G; Renou C; Botta-Fridlund D; Tran A; Portal I; Lecomte L; Castellani P; Rosenthal-Allieri MA; Gerolami R; Ouzan D; Deydier R; Degott C; Halfon P
    J Viral Hepat; 2006 Oct; 13(10):659-70. PubMed ID: 16970597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-invasive biomarkers of liver fibrosis in haemophilia patients with hepatitis C: can you avoid liver biopsy?
    Maor Y; Bashari D; Kenet G; Lubetsky A; Luboshitz J; Schapiro JM; Pénaranda G; Bar-Meir S; Martinowitz U; Halfon P
    Haemophilia; 2006 Jul; 12(4):372-9. PubMed ID: 16834736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FibroTest-ActiTest as a non-invasive marker of liver fibrosis.
    Halfon P; Munteanu M; Poynard T
    Gastroenterol Clin Biol; 2008 Sep; 32(6 Suppl 1):22-39. PubMed ID: 18973844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrotest-Actitest: the biochemical marker of liver fibrosis--the Israeli experience.
    Morali G; Maor Y; Klar R; Braun M; Ben Ari Z; Bujanover Y; Zuckerman E; Boger S; Halfon P
    Isr Med Assoc J; 2007 Aug; 9(8):588-91. PubMed ID: 17877064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of liver stiffness, fibrotest and liver biopsy for assessment of liver fibrosis in kidney-transplant patients with chronic viral hepatitis.
    Alric L; Kamar N; Bonnet D; Danjoux M; Abravanel F; Lauwers-Cances V; Rostaing L
    Transpl Int; 2009 May; 22(5):568-73. PubMed ID: 19196449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of FibroTest-ActiTest with histopathology in demonstrating fibrosis and necroinflammatory activity in chronic hepatitis B and C.
    Uyar C; Akcam FZ; Ciris M; Kaya O; Kockar C; Isler M
    Indian J Pathol Microbiol; 2010; 53(3):470-5. PubMed ID: 20699505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection.
    Poynard T; Zoulim F; Ratziu V; Degos F; Imbert-Bismut F; Deny P; Landais P; El Hasnaoui A; Slama A; Blin P; Thibault V; Parvaz P; Munteanu M; Trepo C
    Am J Gastroenterol; 2005 Sep; 100(9):1970-80. PubMed ID: 16128941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving estimation of liver fibrosis using combination and newer noninvasive biomarker scoring systems in hepatitis C-infected haemophilia patients.
    Maor Y; Calès P; Bashari D; Kenet G; Lubetsky A; Luboshitz J; Schapiro JM; Pénaranda G; Bar-Meir S; Martinowitz U; Halfon P
    Haemophilia; 2007 Nov; 13(6):722-9. PubMed ID: 17973848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noninvasive markers of fibrosis and inflammation in clinical practice: prospective comparison with liver biopsy.
    Anastasiou J; Alisa A; Virtue S; Portmann B; Murray-Lyon I; Williams R
    Eur J Gastroenterol Hepatol; 2010 Apr; 22(4):474-80. PubMed ID: 19887952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [FibroTest-ActiTest for predicting liver fibrosis and inflammatory activity in Chinese patients with chronic hepatitis B].
    Gui HL; Xie Q; Wang H
    Zhonghua Gan Zang Bing Za Zhi; 2008 Dec; 16(12):897-901. PubMed ID: 19105932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discordance between biochemical markers of liver activity and fibrosis (Actitest-Fibrotest) and liver biopsy in patients with chronic hepatitis C.
    Fontanges T; Bailly F; Trepo E; Chevallier M; Maynard-Muet M; Nalet B; Beorchia S; Pillon D; Moindrot H; Froissart B; Slaoui M; Tinel X; Pradat P; Trepo C
    Gastroenterol Clin Biol; 2008 Oct; 32(10):858-65. PubMed ID: 18775614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-invasive evaluation of the liver disease severity in children with chronic viral hepatitis using FibroTest and ActiTest - comparison with histopathological assessment.
    Pokorska-Śpiewak M; Kowalik-Mikołajewska B; Aniszewska M; Pluta M; Marczyńska M
    Clin Exp Hepatol; 2017 Dec; 3(4):187-193. PubMed ID: 29255806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimized stepwise combination algorithms of non-invasive liver fibrosis scores including Hepascore in hepatitis C virus patients.
    Bourliere M; Penaranda G; Ouzan D; Renou C; Botta-Fridlund D; Tran A; Rosenthal E; Wartelle-Bladou C; Delasalle P; Oules V; Portal I; Castellani P; Lecomte L; Rosenthal-Allieri MA; Halfon P
    Aliment Pharmacol Ther; 2008 Aug; 28(4):458-67. PubMed ID: 18498446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of allograft fibrosis by transient elastography and noninvasive biomarker scoring systems in liver transplant patients.
    Beckebaum S; Iacob S; Klein CG; Dechêne A; Varghese J; Baba HA; Sotiropoulos GC; Paul A; Gerken G; Cicinnati VR
    Transplantation; 2010 Apr; 89(8):983-93. PubMed ID: 20335832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?
    Thabut D; Le Calvez S; Thibault V; Massard J; Munteanu M; Di Martino V; Ratziu V; Poynard T
    Am J Gastroenterol; 2006 Jun; 101(6):1260-7. PubMed ID: 16771947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum fibrosis markers identify patients with mild and progressive hepatitis C recurrence after liver transplantation.
    Carrión JA; Fernández-Varo G; Bruguera M; García-Pagán JC; García-Valdecasas JC; Pérez-Del-Pulgar S; Forns X; Jiménez W; Navasa M
    Gastroenterology; 2010 Jan; 138(1):147-58.e1. PubMed ID: 19786026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.